Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Pembrolizumab plus - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Indication: Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

New Indication: Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Study:
  • Phase III, randomized, double-blind, placebo-controlled
  • Advanced-stage, metastatic, or recurrent endometrial cancer of any histologic subtype except for carcinosarcoma
  • Pembrolizumab + Chemotherapy (n=365) vs. Chemotherapy (n=548)
Efficacy:
    dMMR cohort
  • mPFS: NR vs. 7.6 mos, p<0.001
  • 12 mos PFS: 74% vs. 38%, p<0.001
    • pMMR cohort
  • •mPFS: 13.1 vs. 8.7 mos, p<0.001
Safety:
  • Any grade: fatigue (71.6% vs 55.7%), peripheral sensory neuropathy (65% vs.62%), anemia (57.8% vs. 54.7%), nausea (50.5% vs. 41.5%)
  • Grade≥3 AEs: Anemia (19.3% vs. 10.4%), neutropenia (11.9% vs. 17.0%)

N Engl J Med 2023; 27 Mar

Eskander N. Ramez et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

http://doi.org/10.1056/NEJMoa2302312

Reviewed by Elvin CHALABİYEV, MD on APR 17, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More